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Patient-specific cardiac models are now being used
to guide therapies. The increased use of patient-
specific cardiac simulations in clinical care will give
rise to the development of virtual cohorts of cardiac
models. These cohorts will allow cardiac simulations
to capture and quantify inter-patient variability.
However, the development of virtual cohorts of
cardiac models will require the transformation of
cardiac modelling from small numbers of bespoke
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models to robust and rapid workflows that can create large numbers of models. In this review,
we describe the state of the art in virtual cohorts of cardiac models, the process of creating
virtual cohorts of cardiac models, and how to generate the individual cohort member models,
followed by a discussion of the potential and future applications of virtual cohorts of cardiac
models.
This article is part of the theme issue ‘Uncertainty quantification in cardiac and
cardiovascular modelling and simulation’.
1. Introduction
Hindsight is a wonderful thing. If we know what will happen, it is easy to make the right
decision. Biophysical patient-specific models strive to encode known physics and physiology
within mathematical equations and to tune these models to represent individual patients. The
aim is to use these digital twins to predict disease progression, better estimate risk and predict
treatment response so that the outcome might be known before a decision is made. With
sufficiently accurate predictions, the choice of the best treatment for a patient shifts from being
based on the current or past condition of the patient to the future one. While conceptually
simple, the practical reality of determining the equations, tuning the parameters to patient
data and generating reliable predictions remains a significant engineering and mathematical
challenge.
Overcoming such engineering and mathematical challenges has huge potential. Once a
patient-specific model is created, it can then be re-used to design new treatments, evaluate
inclusion criteria, simulate imaging or diagnostic signals, or test mechanistic hypotheses. In
contrast to recent advances in statistical regression models—which are limited to cases where
large datasets are already available—biophysical models are based on physical laws and known
physiological systems and so have greater versatility in their predictions, mechanistic explanatory
power and susceptibility to analysis.
There has been significant investment in the development of biophysical models. Cardiac
modelling, in particular, has made major recent advances in moving patient-specific modelling
into the clinic [1]. The move to human-scale simulations has driven the development of efficient
and scalable code that is required for the simulation of large human hearts [2–4]. The ability to
simulate human hearts increased the ability to tune models to clinical datasets, motivating the
use of image- and signal-processing techniques to convert medical images into data that could
be used to constrain the models. This work has culminated in the recent use of models to guide
therapies in prospective studies of ventricular tachycardia ablation [5], atrial fibrillation ablation
[6] and cardiac resynchronization therapy lead positioning [7].
This shift from developing research or proof-of-concept models to using models in clinical
workflows requires a step change in speed and robustness in model creation [8]. A patient-
specific model needs to be created from standard clinical data robustly and reliably, assessed
and interrogated, all within a short time frame, often less than 24 h. As the cost, in time, of
model creation decreases significantly, this enables the development of large virtual cohorts of
models. These virtual cohorts will allow inter-patient variability to be captured in cardiac model
simulations. These virtual cohorts will allow virtual trials (VTs), which will impact clinical care
through therapy design and development, including patient selection and therapy guidance.
The development of virtual patient cohorts poses new opportunities for cardiac modelling.
How best to move from a cottage industry, where each model is handcrafted, to an industrialized
process where models are produced en masse with limited to no human intervention, is a
challenge. This white paper discusses the current state of patient-specific cardiac models; the
process of developing virtual patient cohorts; how we validate these models; how we quantify
uncertainty at the level of the individual model and at the level of the virtual cohort; and finally
potential and future applications of virtual cohorts.
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Table 1. Patient-specific modelling studies: number of models and study goals.
reference number of patients goal of the study type of model strategy
[9] 35 samples from ex vivo RAA atrial model calibration 0D RVAC
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[10] 4 CRT upgrade; 14 de novo implantation predicting activation with CRT devices BV 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[11] 24 ICM mechanisms for arrhythmia risk
with CRT
LV 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[12] 46 HF building personalized models BV+ T 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[13] 7 clinical cases with ICD building personalized models LV 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[14] 7 PAF cases building personalized models LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[15] 5 CT cases with torso calculating a shock efficiency metric BV+ T 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[5] RS: 5 swine; 21 humans (5 with ICD)
PS: 5 humans
guiding the ablation of
infarct-related ventricular
tachycardia
BV 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[16] 4 PAF; 16 PsAF simulating different ablation strategies LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[17] 12 PsAF simulating ablation of inter-atrial
connections
LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[18] 7 PAF, 5 PsAF simulating AF pre- and post ablation LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[19] 108 PsAF simulating empirical versus
computer-guided ablation
LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[6] 4 PAF; 6 PsAF computationally guided personalized
ablation
BA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[20] 118 PsAF computationally guided personalized
ablation
LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[21] 5 AF patients stroke risk assessment in AF (CFD) LA 1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[22] 70 (training)+ 60 (test)+
3 (12 k samples)
shape uncertainty LA SID
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[23,24] 5 PsAF patient-specific modelling of atrial
action potentials
1:1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CT, computed tomography; CRT, cardiac re-synchronization therapy; HF, heart failure; HCM, hypertrophic cardiomyopathy; ICM, ischaemic
cardiomyopathy; ICD, implantable cardioverter defibrillator; RAA, right atrial appendage; PAF, paroxysmal atrial fibrillation; PsAF, persistent
atrial fibrillation; PS, prospective study; RS, retrospective study; 0D, cell model; BV, bi-ventricular; LV, left ventricle; BV+ T, bi-
ventricular+ thorax; LA, left atrium; BA, bi-atrial; 1 : 1= 1 : 1 mapping virtual cohort; SID, sampling from inferred distributions; RVAC,
random variation with acceptance criteria.
2. Examples of virtual cohorts of cardiac models
Table 1 provides an overview of representative studies which used virtual cohorts of cardiac
models. To date, these studies have included a relatively small number of individuals, between
5 and 100 virtual patients. In contrast, algorithmic studies may be applied to much larger clinical
datasets; for example, Pennells et al. computed cardiovascular disease risk algorithms using data
from 360 737 participants by pooling data across 86 prospective studies [25]. Constructing virtual
patient computational modelling cohorts on such a scale is not currently possible because of
the challenges associated with data availability, as well as the time and specialist methodology
required to construct these detailed biophysical models.
The studies in table 1 focused on aspects of model construction and calibration, on
obtaining mechanistic understanding of a disease or on predicting response to a therapy.
For example, Cedilnik et al. presented a modelling pipeline for constructing fast personalized
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cardiac
virtual cohorts
(iii) random sampling with
 acceptance criteria
(i) 1:1 mapping virtual
cohorts
(ii) sampling from inferred
distributions
1:1
P1 ~ N1(m1, s 12)
Pi ~ Ni (mi, s i2)
inference of mi, s i2, Cov (Pi, Pj)
random guess of mi, s i2, No Cov (Pi, Pj)
Pi ~ Ni (mi, s i2)
P1
P2
Pi
P2
real patient virtual patient
Figure 1. Schematic of the strategies for obtaining a virtual cohort, based on biophysical models. (Online version in colour.)
ventricular models using an eikonal formulation [13], demonstrating their methodology on
seven CT and electrophysiology datasets. Corrado et al. [14] presented a workflow to build
personalized computational models from local multi-electrode catheter measurements and
applied the technique to data from seven paroxysmal atrial fibrillation clinical cases. Kayvanpour
et al. generated a larger cohort of models consisting of 46 heart failure patients, incorporating
personalized anatomy, electrophysiology, biomechanics and haemodynamics [12]. As well as
personalizing the cardiac anatomy, models may include a torso mesh from imaging data [15].
The effect of variability is also important; Muszkiewicz et al. investigated this by integrating
cellular-level and ion channel recordings in human atrial models using right atrial appendage
measurements from 35 patients [9].
Multiple studies have used computational models to test response to therapies, including
ablation of atrial arrhythmias [16–19], ablation of ventricular arrhythmias [5], CRT optimization
[10] and ventricular tachycardia risk assessment following CRT [11]. These studies vary in the
degree of model complexity and personalization included and the size of the virtual cohort. For
example, atrial ablation studies range from smaller studies, incorporating left and right atrial
fibrosis distributions in bilayer models (n=12 [17]), or left atrial volumetric models including
transmural fibrosis (n=12 [18]), to large studies using left atrial shell models for which only the
anatomy was personalized (n=108 patients [19]).
3. Approaches to generating a virtual cohort of cardiac models
The aim of virtual cohorts of cardiac models is to account for inter-patient variability in simulation
studies. A virtual cohort consists of multiple members, where each member of the cohort has a
distinct parameter set. The variation in parameter sets and anatomy between members aims to
represent the variability in the true patient population.
(a) Strategies for generating virtual cohorts
The parameter set for each member of the virtual cohort can be obtained in three ways: first,
by having each member of the virtual cohort represent a specific patient from a real-world
cohort (1:1 mapping); second, by generating a parameter set from inferred parameter distributions
(sampling from inferred distributions); and, third, by completely randomly generating parameters
and testing if these result in physiologically plausible models (random variation with acceptance
criteria). Figure 1 gives a schematic summary, while the methods are detailed below.
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(i) 1:1 mapping virtual cohorts
The development of 1:1 mapping virtual cohorts incrementally builds on current techniques
for creating models of a specific patient’s heart: it repeats this process multiple times in order
to generate a number of specific models that, in turn, form the virtual patient cohort. While
superficially simple, the process of repeating the patient creation workflow on new patients
is often subject to subtle variations or the effect of artefacts in clinical data. Manual steps
quickly become bottlenecks, data structures need to be standardized and cost functions that were
tailored to the first case need to be generalized for all cases. In addition, the first case is always
built on the best and most complete data. Moving to multiple cases exposes the challenges of
obtaining multiple high-quality datasets from specific patients. This makes data collection for the
generation of large virtual cohorts time-consuming and expensive. Nonetheless, the availability
of data is essential also for other strategies aiming at the construction of virtual cohorts, and a
number of research groups are working on this area, addressing each of challenges mentioned
above [1,24,26–29].
(ii) Sampling from inferred distributions
In cases where a 1:1 mapping virtual cohort can be created for a representative subset of a
population, it is possible to also infer the parameter variability and co-variability. This allows
one to model the parameters as following a statistical distribution. By sampling from these
distributions, new parameter sets can be generated representing new virtual members of the
patient population. The statistical distribution of the parameters can be assumed to be of known
form—for example, Gaussian. The task, in this case, reduces to using the data to estimate
the hyper-parameters of the distribution—corresponding to the mean vector and the variance–
covariance matrix in the Gaussian example. Alternatively, if there are no principled reasons
to assume a known form for the parameter distribution, this can be inferred applying either
Bayesian statistical methods [30] such as Markov chain Monte Carlo (MCMC) [31], or frequentist
techniques such as bootstrapping [32], to individual or cohort data. The resulting parameter
distribution is a discrete (or sample) approximation of the underlying distribution. In both
Bayesian and frequentist approaches, parameter sets for members of the virtual cohort can then be
generated by drawing from the inferred distributions that have the property of representing the
variance and covariance structure of the parameters emerging from the data. While this approach
allows estimation of the effects of population variance, there are no guarantees that the generated
cohort members will be physiologically plausible and, ideally, each member model should be
evaluated to ensure a physiological plausibility.
(iii) Random variation with acceptance criteria
In situations where the variance and co-variance of the model parameters is unknown, and
sufficient measurements to infer a distribution of parameters are not available, then it is possible
to generate large numbers of parameter sets by randomly varying parameters to generate new
members of a virtual cohort. Variations of this approach were first taken by [33,34]. It is possible
for each proposed member of the virtual cohort to be evaluated against population measurements
and only models that fall within these physiological bounds to be included in the virtual cohort, as
performed in [35] and subsequent papers. This is a robust method, which is simple to implement,
and allows virtual cohorts to be built when limited data or summary statistics or processing
time are available, and provides measures of how parameter variability might affect results,
by producing high-dimensional plausible regions in the parameter space. Differences between
virtual cohorts can then be evaluated by the degree of overlap in model predictions generated
by the population. However, despite the formal similarity to the MCMC accept–reject procedure,
the method fails to account for co-variation in model parameters and measured phenotypes;
the parameter sets that are generated are possible but there is no guarantee that they occur
physiologically; as more variables are added to define acceptance criteria, it becomes less likely
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(ii)
machine learning approaches for
mapping data to parameters
(iii)
machine learning approaches for
model emulation (iv)
improving validation in
cohort models
(iii)
validating cohort models
output
(i)
model validation in
biomedical applications (ii)
challenges in validating
individual models
(v)
using exp./population data
designing virtual cohort member
model templates
constraining parameters in virtual cohorts of
cardiac models
validation processes of cardiac
virtual cohorts
(iv)
identifiability and UQ
(iii)
I/O sensitivity(ii)
clinically relevant
(i)
physiologically
relevant
(i)
Bayesian approaches to constraining
patient parameters
Pi
(a) (b) (c)
Figure 2. Process of creating a virtual cohort. (a) Defining a template model structure for the members of the cohort,
(b) constraining the parameters for the members of the virtual cohort and, (c) validating the models representing specific
individual patients and the virtual cohort. (Online version in colour.)
that any individual is near the mean of the multivariate population distribution; finally, while
parameter sets are generated these are not samples from probability distributions, so standard
statistical tests for differences between populations should not be applied.
(b) Synthetic versus patient-derived members of the virtual patient cohort
The strategies for model development can be separated into development of synthetic virtual
patients, where virtual patients are generated by sampling from distributions (whether inferred
or guessed and not-rejected) and patient-derived virtual patients, generated using the 1:1 mapping
approach, in which case the virtual patients correspond to actual real people. While the data
cost for each patient is high in the 1:1 mapping approach, this does provide some guarantee
that each virtual patient’s heart will operate within some physiologically plausible space. In
the case where only a limited number of models can be made, due to time or data restrictions,
using a 1:1 mapping approach has the potential for patient-specific bias. The bias, if any, can
potentially be estimated by comparing emergent model phenomena with population statistics
from larger clinical trials or from population databases. On the other hand, the generation
of synthetic virtual patients allows speculative studies to evaluate what could potentially
happen in extreme edge cases. This could be useful when trying to identify rare events or
edge patient cases, who may not be represented in available patient cohorts. However, this
approach runs the risk of creating non-physiological or implausible models that can skew the
results for the virtual cohort, especially in the case where parameters are randomly guessed.
However, once 1:1 mapping cohorts of sufficient size have been generated, these provide
better bounds and parameter distribution estimates for constraining synthetic virtual patient
approaches.
4. Constructing, constraining and validating virtual cohort models
Creating a virtual cohort requires the development of a template model for representing each
member of the cohort. The template needs to be carefully designed to be able to capture patient
variability, physiology, diseases and treatments of interest. In cases where the model is tied to
clinical data for specific patients, the model complexity needs to reflect the available clinical
data and the time and resources available to create the model. In virtual cohort strategies, where
models need to be tuned to represent all or a subset of specific patients, the model parameters
must be inferred using nonlinear optimization, statistical or machine learning approaches.
The constrained model is subsequently exposed to a validation step, in order to assess its
generalization properties for predictions tasks. These three steps are depicted graphically in
figure 2.
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(a) Designing virtual cohort template model templates
A virtual patient cohort is made of virtual members who all share a common model structure.
This means that variability is encoded in the anatomy, physiological parameters and boundary
condition parameters, as opposed to differences in model structure. As with previous cardiac
biophysical models, while the initial aim of a virtual patient cohort may be specific, if virtual
cohorts are to be reused outside of their original application, the model template will need to
be designed to be generic, reusable and easy to manipulate, allowing simulations to be run
and analysed at scale. Ideally, the model template will be combined with a definition of the
physiological envelope within which the member and virtual cohort models have been validated
to ensure appropriate use and reliable predictions.
(i) Physiologically relevant virtual cohort member model templates
The model template must encode physiologically relevant mechanisms for the virtual cohort
application. The level of physiological detail in a model template needs to balance complexity
versus the ability to constrain model parameters.
Increased complexity is motivated by the lack of a clear set of known important physiologically
relevant mechanisms and the desire to make a general virtual cohort that can be applied to
multiple applications. However, complex biophysical models often rely on representative or
population parameters and this may miss important patient-specific physiology aspects. By
contrast, the use of simple models is motivated by the intent of constraining most (if not all)
the model parameters to be patient specific, as well as the inability to precisely constrain all the
parameters of a complicated model by the available data, and the need to contain simulation costs
[23,36].
As a minimum, when tested, simulations of individual patients within the virtual cohort
should be able to reproduce the corresponding clinical measurements from that patient to within
a specified tolerance. The model parameters and predicted phenotypes should be prescribed into
the mathematical model structure to ensure that the model captures fundamental physiology and
that parameters are globally identifiable from the available data [37].
(ii) Clinically tractable virtual cohort member model templates
As described, cohorts of virtual patients can be created in two ways. First, synthetically by
sampling parameter distributions, as part of an offline focused project to create a virtual patient
cohort. Second, from a cohort of patient-derived virtual patients created as part of a clinical trial
or routine clinical care. When models need to be made at scale, or as part of the clinical workflow,
the time taken to create each model becomes critical. As models in the near future are likely to be
created as an adjunct to standard clinical practice, the data used to constrain model parameters
and validate model predictions need to reflect available clinical data. Adhering to these two steps
will allow virtual patient cohorts to fit directly into clinical applications, in which parameters are
inferred by matching patient physiological dynamics [38].
(iii) Parameter and predicted phenotype sensitivity of virtual cohort member model templates
Model sensitivity is another important challenge in designing the virtual cohort member template
model. Sensitivity is defined as the rate of change in simulated model predictions or outputs
in response to changes in model parameters. For an example, see [39]. In biophysical cardiac
models, the mapping from patient data to simulation predictions can be separated into two steps.
First, the dependence of model parameters on input data can be determined. This sensitivity
can be used for informing how values are measured [40,41], for example choosing between
echocardiography, MRI or CT to measure cardiac mechanics to achieve a desired precision in
inferred model parameters. Second, the dependence of the model outputs on model parameters
can be determined. Parameters to which the model output of interest is relatively insensitive may
not need to be personalized, whereas parameters to which the output is highly sensitive may
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need to be precisely personalized for each patient. Examples of sensitivity analysis applied to
cardiovascular diseases, where model output measures are used to reflect clinical goals, can be
found in [42,43].
(iv) Identifiability and uncertainty quantification of virtual cohort member model templates
In cases where models are based on patient-specific clinical data, the template model parameters,
or a defined subset, should be derived from the available data. In the case where a single
deterministic parameter set is used to reflect the physiology of each member of the virtual cohort,
the model parameters should be uniquely identified for each specific patient. However, there is
growing application of uncertainty quantification (UQ) to patient-specific models. Within this
framework parameters are defined by distributions as opposed to a single value. The distribution
of a parameter for a given patient represents the uncertainty of the true parameter value for that
patient. An advantage of the UQ approach is that it provides a natural framework for predictions:
these are simply generated from multiple instances of the same patient, with parameters
randomly sampled from the distributions in each simulation. In both cases, the creation of a
virtual cohort based on the inferred parameters identifies a population level distribution.
(v) Using experimental or population data in virtual cohort member model templates
The need to capture physiologically relevant mechanisms, create identifiable models and develop
models rapidly and robustly has led to pragmatic modelling choices. For example, in tissue
electrophysiology simulations, detailed representative biophysical cell models are used that are
not tuned to the individual patient [5,6]. However, these models capture the complex interplay of
cellular electrophysiology and calcium dynamics that are important in arrhythmia simulations
and allow qualitatively relevant predictions to be made that have been successfully used to
inform patient treatment. Setting a non-personalized parameter to a single fixed value is often
the only practical option due to computational resource constraints. However, it would be more
correct to view non-personalized parameters as uncertain and specify them using probability
distributions, ideally representing population variability in that parameter conditional on known
information about the patient (e.g. on sex or age). This approach is currently infeasible for
whole-heart patient-specific models due to both computational cost and lack of information on
population (and sub-population) variability for the wide assortment of functional parameters
in cardiac models. However, the increased availability of population databases, for example
the UK biobank [44] and, in the future, the availability of virtual cohorts of cardiac models,
will provide population-based priors for informing some non-personalized model parameters
in individuals. This will allow more sophisticated models to be made that are informed
by a combination of population and patient-specific data, and that fits more and more the
UQ paradigm.
(b) Constraining parameters in virtual cohorts of cardiac models
With the rapid growth of clinical and consumer sensor technology, which make the gathering
of large individual and population patient data readily available, there is an increasing need for
accurate big data analytics to construct and constrain virtual cohorts of cardiac models. The tools
are supplied by emerging fields such as big data informatics and machine learning [45,46], used
to inform model parameters from large datasets. For example, modern deep data techniques
can be used to analyse and constrain larger numbers of model parameters, which increases
understanding of how patient-data could be used and shared. On the other hand, machine
learning—especially its probabilistic version [47]—provides efficient approaches for clustering,
dimensionality reduction and constraining models. These methods are thus becoming ubiquitous
in the way virtual cohort models and data are used in medicine.
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(i) Nonlinear optimization and Bayesian approaches
The most intuitive approach for constraining the parameters of a cardiac physiological model is
to minimize a cost function that represents the distance between the model evaluated in a given
set of parameters and the data. A number of cost functions can be considered, that, for example,
weight differently each data point, or that add a penalty of some sort on the magnitude of the
parameter vector. The task is thus to find the values of the parameters by means of iterative
nonlinear optimization algorithms [48–50], where the nonlinearity is intrinsic in the way the
parameters enter the cardiac model. The main drawback of this approach lies in the multimodality
of the cost function: this is both a computational challenge for numerical algorithms, which need
to have the ability to learn multiple minima, and it poses interpretability issues in a case where
there is not a unique global minimum.
A natural solution is offered by Bayesian inference, that forms a large part of the UQ
methods mentioned above. In fully Bayesian approaches, a prior belief on the parameters (a
distribution with typically population-based parameters) is modified to a posterior belief by
means of observed patient data, whose information is modelled through the chosen likelihood
function. Inference corresponds, thus, to the ability of sampling from the posterior distribution
of the parameters: this is, for example, the key step for obtaining predictions from the model,
as explained above, but another typical task is using the samples to approximate integrals of
interest (for example, the posterior mean). MCMC methods are the main class of algorithms for
full posterior sampling with batch data, based on a principled accept–reject scheme. When the
data are seen as arriving sequentially in time or space, and one wants to capture the intrinsic
stochasticity of the sequential data, the corresponding class of Bayesian learning algorithms is
provided by sequential Monte Carlo methods [51]. These generalize the Kalman filter to non-
Gaussian data and nonlinear models; we refer to [52] for an electrophysiology example, aimed at
constraining the Mitchell and Schaeffer model. A number of challenges arise in these seemingly
easy procedures, primarily related to the difficulty of designing efficient proposal distributions,
especially when the parameter of interest is high-dimensional and the posterior is multimodal.
Computational solutions have been provided by means of (i) approximation of the posterior,
as in variational Bayes approaches [53], approximate Bayesian computation, [54,55], posterior
tempering [56] and dimension reduction [57]; (ii) direct exploitation of the geometry of the
posterior [58]; (iii) state-space augmentation to ease the inference [59]. Finally, restarting MCMC
methods multiple times from different initial points allows one to identify at least some of the
different posterior modes, and to design a sampler with improved capacity of exploring high
probability regions.
(ii) History matching approaches
When the variance–covariance structure of the parameters is not of strict interest, or it too
costly to obtain, history matching (HM) provides an approach to constrain the parameters
to plausible regions. The model is evaluated for a large space-filling design of parameter
values (e.g. latin hypercube), which are accepted or rejected based on an implausibility
criterion. As an example, in [60], HM is used to constrain a subset of the parameters of
the Courtemanche and the Maleckar cell models. The main difference between the MCMC
and the HM acceptance criteria is that the former, if successfully converged, guarantees that
all the accepted parameter values are (correlated) samples from the posterior distribution,
although to assess the convergence of MCMC chains remains a challenging task in itself
[61]. The latter simply identifies regions of the parameter space that are consistent with the
measured data, trying to account for uncertainty in both observations and predictions, but
without guarantees. To tackle the computational burden of evaluating a very large number of
samples, MCMC and HM often rely on a model surrogate or emulator, as described in a later
section.
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(iii) Machine learning approaches for mapping data to parameters
Data-driven machine learning has the advantage of extracting complex relationships from large
amounts of data, giving a model which later can be executed efficiently for time-sensitive
workflows. This approach will complement virtual cohorts of cardiac models that are biologically
and physiologically sophisticated but face challenges in assimilating data from different sources
in a timely fashion. There are thus many opportunities for integrating machine learning methods
with virtual cohorts of cardiac models.
Machine learning models can be trained to learn a direct mapping between model parameters
and outputs generated by virtual cohorts of cardiac models, which can later be used to allow
a fast calibration or UQ of virtual cohorts of cardiac models when given clinical data. In [62],
a polynomial regression model was trained to predict myocardial electrical diffusion from
simulated ECG data, which was then used for fast calibration of a cardiac electrophysiology
model from clinical ECG data. Similar ideas were explored in [63,64] for personalizing cardiac
electrophysiology models from higher density surface ECG data. In [65], linear regression models
and decision trees were learned to map input geometrical features to simulated haemodynamic
features, which were then used for quantifying the uncertainty in haemodynamic outputs as a
result of geometric uncertainty. These approaches provide an attractive time-effective alternative
to calibrating or quantifying the uncertainty in virtual cohorts of cardiac models in clinical
workflows, in contrast to traditional optimization and statistical inference which are typically
computationally expensive. The challenge regarding the multi-modality or non-identifiability of
the parameter given available data, however, still remains, highlighting the importance of UQ
to characterize the probabilistic distribution in the model parameters even in machine learning
approaches [66]. An additional challenge arises from how well the machine learning relationship
trained on simulation data may generalize to clinical data, and this approach was suggested as a
preliminary step prior to more refined model personalization in [62,67].
(iv) Machine learning approaches for model emulation
With the rapid growth in their modelling capacity, data-driven deep learning models may also
have a role in directly approximating the simulation model for the purpose of accelerating data
assimilation in virtual cohort models that are otherwise computationally prohibitive to realize.
Similar to earlier surrogate/emulator models such as polynomial chaos and Gaussian process,
the fundamental idea is to learn to approximate the simulation-based solutions and then use
these computationally efficient surrogates in later tasks such as data assimilation [68,69], which
traditionally consists of the optimal integration of typically sparse real-world olbservations to
improve model estimates such as forecasts or state reconstructions [70]. This is rather appealing
for enabling data assimilation of virtual cohort models at scale, although several challenges
remain to be addressed. To build the training database from simulation remains time-consuming,
and it is not clear how exhaustive the simulation needs to be in order for the machine learning
surrogate to be able to mimic the simulation model over a wide range of parameter values [71,72].
(c) Validation of virtual cohorts
Validation is the process of assessing whether a model is suitably representative of the physical
process it seeks to represent and therefore whether predictions from the model are sufficiently
close to those of the real system. It should be noted that there is no such thing as a validated
model, but rather a body of evidence that the model produces results which are consistent with
the physical system being modelled in a specified regime or parameter space. While a model may
generate accurate predictions within one region of parameter space, it may not necessarily extend
to producing reliable, or even physiologically plausible, results outside of that region [73]. Our
confidence in a specific model output should, therefore, reflect its position relative to the regime
in which validation has been undertaken. Furthermore, models will often predict variables that
can not be or were not measured directly, for example stress in cardiac mechanics models. These
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variables can be of interest for understanding mechanisms underpinning emergent observations.
There will be less confidence in these model predictions that can not be compared against
experimental data. However, confidence in the model prediction can be gained if the model is
physics based and is validated across a wide range of conditions that alter the unmeasured model
output.
(i) Challenges in validating individual models
Cardiac models are often highly complex, frequently spanning multiple scales, from tissue
properties to individual ion channels. Each of these sub-components includes assumptions and
parameters for which evidence supporting their representation of reality should be sought. Few
parameters correspond to directly observable quantities, requiring inference procedures in order
to incorporate these observations into the model. These may use simple approaches (such as
linear regression), or necessitate the use of more sophisticated statistical models to tease out
the relevant associations. For example, tissue conductivity in homogenized models cannot be
measured experimentally/clinically. Statistically, models can be used to associate this quantity
with an observable, such as conduction velocity. In calibrating a cardiac model to an individual,
observations are often only acquired in a small region of the parameter space (e.g. during pacing
or sinus rhythm) or at low spatio-temporal resolution, depending on time, practical and ethical
constraints. The process of validation often requires evaluating the model multiple times; the
complex nature of whole-heart cardiac models can make this computationally expensive and
time-consuming, adding further challenge to the validation process.
(ii) Validating cohort models
These issues are further compounded when looking to validate cohort models. Independent
of the approach used to generate the cohort model, we would like to validate it against real
patient observations, or real cohorts of patients. The method used to generate the virtual cohort
strongly impacts the ability to perform validation. For example, virtual patients generated using
the 1:1 mapping method correspond to actual patients, from which other data can be obtained
for validation. Synthetic virtual patients, on the other hand, cannot be validated in the same
way, as there is not a corresponding real patient to compare against. Cohorts of either type can
be validated in a statistical manner by comparing cohort-level statistics against population-level
statistics. Owing to the significant challenges in performing this validation, evidence supporting
the validity of biophysical models in the existing literature tends to be sporadic and ad hoc.
At the cellular scale, efforts to validate action potential models are generally quite prevalent.
While verification of computational implementations of tissue-scale modelling has been proposed
[74,75], limited validation against actual patient data is found in many whole-heart modelling
studies [14]. Many cohort studies cite evidence supporting their validity from previous studies,
which in turn cite earlier studies which ultimately provide limited actual evidence in themselves.
(iii) Improving validation in cohort models
To improve validation, each study should be able to reference a body of primary evidence
(rather than earlier studies using the model) supporting the components of the model being
used from earlier work, and include evidence that the model as a whole is representative of
the population it aims to represent. This may include some cohort-level validation steps taken
within the study, but also explicitly citing validation data for sub-components used, such as
assessments of tissue-scale and action potential models, and their calibration methods, for the
individual simulations within the cohort and for the regimes under consideration in the study.
This procedure should be used in helping to establish the validity of results, and consequently
the strength of conclusions drawn during the peer-review process. This process would be made
more effective through the pursuit of specific (multiple, independent) validation studies, either
published through traditional journals or as white papers on pre-print servers, which includes the
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raw data used. As part of this validation process, quantification and propagation of uncertainties
in sub-components must inevitably play a role. Substantial work has already been done in the area
of UQ for action potential models [76,77], but this needs to be propagated through to whole-organ
models and cohort models [22]. Stating that a given outcome is the most likely outcome, given
the available data, is a much stronger statement than a given outcome is plausible. Achieving all
this, and being transparent about the extent to which the constituent components are themselves
validated, will provide greater strength to cohort studies and document a clear and unambiguous
provenance of validation evidence to support their use.
5. Potential and future applications of virtual cohorts of patient models
The creation of virtual cohorts of cardiac models are a relatively new innovation in cardiac
modelling. These ideas have been proposed and adopted in other fields of computational
modelling [78–80], including cardiovascular [81,82] and thymus modelling [83] as well as
modelling of insulin and glucose [84,85], pacing lead design [85] and immunomodulation
[86]. Currently, as described above, cohorts of cardiac models are being developed for specific
applications to answer clinical or scientific questions. However, as the number of virtual cohorts
developed and made publicly available increases, so too will the applications of these models.
(a) Trial outcome prediction/proof of concept
One potential use of virtual cohorts is to simulate a clinical trial in advance of investing in the
actual clinical trial. Assuming the simulations are expected to reliably predict the clinical endpoint
of interest (difficult to ensure in practice), the advantages are clear: millions of dollars could be
saved if the VT prevents a failing trial going ahead. For example, in [87], the authors used a VT to
retrospectively re-create the results of the Rhythm ID Goes Head-To-Head (RIGHT) trial, which
compared performance of two ICD devices. The conclusion of the RIGHT trial was the opposite
of what had been hypothesized at the time; the virtual result reproduced this result.
(b) Responder identification
Related to prediction of trial outcomes is the use of virtual cohorts to identify individuals who
are likely, or not likely, to respond to the therapy, for example by identifying sub-populations
within the intended patient population for which the proposed therapy is not likely to be effective.
Studies using virtual cohorts could be used to derive better inclusion–exclusion criteria for the real
trial, to reduce the size of the trial while maintaining adequate power. This could, depending on
the effect size, ultimately be the difference between trial success or failure.
(c) Trial augmentation and reduction
It has been proposed that some clinical trials could be augmented with a corresponding VT.
Results from the VT, if they agree with the real-world trial, could be used to end the real-
world trial earlier than initially planned. The medical devices community, via a collaboration
facilitated by the medical devices innovation consortium (MDIC), has recently developed a
Bayesian statistical framework for the formal integration of VT data and a real-world trial. The
basic idea is a VT is performed in parallel with the real trial, and VT results are weighted according
to the extent that they match the real-world trial. Specifically, the number of virtual patients used
is controlled by a discount function which uses the similarity between modelled and observed
data. This is a powerful approach because it reduces the (pre-use) validation burden for the
computational models; results from the VT will essentially be discarded if they fail to match the
real-world trial. The approach is described in [88].
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(d) Simulate situations for which clinical trials would be unethical
Virtual cohorts are already used in some applications to provide data for regulatory submissions,
where performing a clinical trial would be impossible. Most notably, computational modelling
has been used to evaluate safety of metallic implantable medical devices when the patient
is exposed to the radiofrequency electromagnetic radiation during MRI. Implanted devices
may heat and cause thermal tissue damage during MRI. Performing clinical trials to study
whether heating remains within safe limits presents too great a risk to patients. Therefore,
electromagnetic computational simulations are routinely used to predict potential MR heating
for new implantable devices. A range of virtual patients—in this case, detailed whole-
body anatomical models with electromagnetic material properties for each tissue—have been
developed for these purposes. The virtual population [89] is a set of virtual patients, covering
a range of ages, BMIs and both sexes. Some members were generated from segmentation of data
from real subjects, others through morphing (synthetic virtual patients). Simulation studies using
the virtual population have been used to establish RF safety in regulatory submissions for scores
of devices [90].
(e) Training machine learning algorithms using virtual cohorts
Virtual cohorts can be combined with machine learning approaches to generalize knowledge
gained in virtual cohorts to future patient groups. In this setting, virtual cohorts have the ability
to generate the high volumes of data required by machine learning and deep learning models that
are otherwise difficult, expensive or impossible to obtain in experimental/clinical environments.
This provides a way of generating low-cost high-volume synthetic data to initialize machine and
deep learning models, which can then be retrained on potentially smaller but more relevant
datasets. At the same time, machine learning models can mine from data generated by virtual
cohort models and convert it to actionable knowledge for decision-making in the future. Several
challenges exist in this process. How to address the discrepancy between the virtual cohort
models and the reality? How to introduce sufficient variations in the virtual cohorts such that the
derived machine learning models can generalize well when applied? Rapid advances in related
machine learning concepts such as transfer learning and domain adaptation are likely to help us
resolve these challenges, as demonstrated in recent work [64,91].
(f) Virtual trials replacing clinical trials
The above applications use virtual cohorts to improve trial design (including whether to perform
a clinical trial at all), reduce the size of a trial, provide evidence when a clinical trial is not possible
or develop new algorithms. Ultimately, the holy grail for virtual cohorts is to replace clinical trials
that are currently used to establish safety and efficacy/effectiveness of medical products. The
current exponentially increasing cost of bringing medical products to market demonstrates the
urgent need for cheaper, more efficient (but equally reliable) methods; computational modelling
provides one potential solution [92]. Should virtual cohorts become successful in the above
applications, it may become feasible for some clinical trials to be replaced by VTs. However,
the current limited use of virtual cohorts in the above applications demonstrates that we remain
far from this ambitious goal. The numerous challenges described throughout this paper, both
related to cohort development and validation, will need to be robustly addressed, as will other
challenges, for example, the social challenges of ensuring public confidence in such approaches.
6. What is needed to extend the application of virtual cohorts of cardiacmodels
(a) Creating member template models with a hierarchy of complexity
Virtual cohorts of cardiac models should include member template models that contain models
of different complexity and possibly should have modular structure. The top-end models should
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be based on the best available imaging of the object and should include detailed multiscale
representation of all involved physiological properties with proper description from (sub)cellular
to the whole organ level. However, we should also have a hierarchy of models for the same
patients with lower spatial accuracy and a more generic description of physiological properties.
The type of model used should be dictated by its specific application. The creation of top-end
models still remains challenging due to problems with proper data collection and also due to
insufficient understanding of some underlying physiological processes.
(b) Omics driven models
In view of the huge amount of data obtained using genomics and proteomics data, it would be
useful to connect the cardiac model parameters to the characteristics measured from omics. One of
the most straightforward ways to do this would be to use widely available mRNA expression data
and tune conductivities for the corresponding ion channels [93]. Another interesting approach
was recently proposed in [94], which uses a novel methodology of Cap-Analysis of Gene
Expression to tune model parameters to patient-specific data. In addition, as we obtain more and
more data on cell regulatory systems, it would be good to add such data to electrophysiological
models as was done, e.g., by Tan et al. [95] for cardiomyocyte mechano-signalling. It would be
good to extend similar approaches to other regulatory systems.
(c) Modelling tissue substrate
The fine structure of cardiac tissue is very complex and heterogeneous, and its features have
a significant impact on heart function. Usually, the micro-anatomical organization of cardiac
myocytes is modelled by spatial fields of cardiac fibre-sheet. The conduction system, in particular
the Purkinje network (PN), is another structure that critically influences cardiac function [96].
Ex vivo imaging provides valuable information that has motivated the development of different
rule-based models for both fibre-sheet fields and the PN. Unfortunately, these rule-based models
are not patient-specific, and recent studies revealed that uncertainties on fibre-sheet fields [97,98]
and on the PN models [99] considerably impact the results of cardiac simulations. Fibrosis is
present in many cardiovascular diseases, and it is known to participate as both trigger and
substrate of arrhythmias. Many proof-of-concept studies have shown the importance of the cell-
scale and intricate pattern of fibrosis [100,101]. However, today’s non-invasive techniques only
provide coarse-grained information about its location and shape. In the absence of fine-grained
characterization of fibrosis, the amount of uncertainty significantly increases and challenges
patient-specific modelling. In [29], to evaluate the pro-arrhythmic nature of a fibrotic region,
the construction of a patient-specific model involved a collection of 500 biventricular models,
each one representing a different but yet possible cell-scale pattern of the patient’s fibrotic
region. Fortunately, emerging imaging techniques are expected to contribute with patient-specific
information about the fine structure of cardiac tissue [102].
(d) Publicly accessible virtual cohorts
The creation of patient-specific cardiac models requires access to patient data, access to tools to
process the data and access to the compute resource required to run simulations to fit the model to
the data. These all represent barriers to research groups developing patient-specific models, using
virtual-patient cohorts or creating software to process and analyse simulation outputs. Recent
interactive tools exploiting the computational power of relatively low-cost graphics cards [24]
are designed to increase accessibility and can form the basis of a virtual-patient workflow. While
repositories have been created for sharing patient data on public databases, for many groups
this is not possible due to the use of historic data, data policies or question on data ownership.
However, fully anonymized computational models of patients hearts that contain no clinical data
are a lower barrier to sharing publicly. The publishing and sharing of virtual cohorts of cardiac
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models—analogous to the successful approach adopted in cardiac cell modelling—will accelerate
the development and adoption of virtual cohorts of cardiac models.
7. Discussion and conclusion
The development of detailed biophysical virtual patient cohorts of cardiac models is an area
of great potential but with many technical challenges. Interacting with industry and regulators
will be important for the translation of virtual cohorts of patients into industrial and clinical
tools. Modelling applications, including physiologically based pharmacokinetic models, provide
an exemplar process for how to develop and validate models for use in clinical applications.
Similarly, the use of models by industry in low regulatory early phases of device, drug or
product development will provide a real-world context for developing and applying virtual
patient cohorts. The increased complexity and computational cost in moving from a single patient
to multiple patient modelling studies will require the creation of shared community resources.
Improved access to simulation software, virtual cohorts of patients and model personalization
workflows will facilitate the development and adoption of this modelling approach, and also
reduce the number of projects that are forced to re-invent the wheel.
Virtual cohorts of cardiac models provide a low-cost tool for quantifying the impact of
patient variability on physiology, pathophysiology and treatments. The ability to perform low-
cost simulations over a meaningful representation of a patient population is an important step in
the translation of computational models of the heart into industrial and clinical applications.
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